Related Experiment Videos
Acute psychostimulant challenge in primary obsessive-compulsive disorder
R T Joffe1, R P Swinson, A J Levitt
1Department of Psychiatry, Toronto General Hospital, Ontario, Canada.
Journal of Clinical Psychopharmacology
|August 1, 1991
Summary
Dextroamphetamine, unlike methylphenidate, significantly reduced obsessive-compulsive disorder symptoms compared to placebo. This suggests catecholamines, not just serotonin, may play a role in OCD pathophysiology.
Area of Science:
- Neuroscience
- Psychiatry
- Pharmacology
Background:
- Obsessive-compulsive disorder (OCD) is a debilitating mental health condition.
- Current treatments for OCD have limitations, necessitating exploration of novel therapeutic avenues.
- Psychostimulants are known to affect neurotransmitter systems implicated in OCD.
Purpose of the Study:
- To compare the acute effects of dextroamphetamine and methylphenidate against placebo in patients with primary OCD.
- To investigate the potential role of catecholamines in the pathophysiology of OCD.
Main Methods:
- A double-blind, placebo-controlled study involving 11 patients with primary OCD.
- Acute oral administration of methylphenidate (40 mg), dextroamphetamine (30 mg), and placebo.
- Symptom severity assessed using the Comprehensive Psychiatric Rating Scale--Obsessive-Compulsive Subscale.
Main Results:
- Dextroamphetamine demonstrated a significantly greater reduction in obsessive-compulsive symptoms compared to placebo.
- Methylphenidate did not show a significant antiobsessive-compulsive effect compared to placebo.
- Observed effects were independent of changes in depression, though differential effects on anxiety were noted.
Conclusions:
- Dextroamphetamine shows promise as a treatment for OCD, suggesting a role for catecholaminergic pathways.
- The differential effects of dextroamphetamine and methylphenidate highlight the complex neurobiology of OCD.
- Further research into psychostimulants and catecholamine function in OCD is warranted.